Survodutide for weight loss: what patients should know

Patients have started asking me about survodutide by name, usually after reading that it is "the next Mounjaro." It is a genuinely interesting medication, but it is not yet available and there are details worth understanding before you decide it is the one you are waiting for.

What survodutide is

Survodutide is a once-weekly injection that activates two hormone receptors at the same time: GLP-1, the familiar target of semaglutide (Wegovy) and part of tirzepatide (Mounjaro), and the glucagon receptor.

That second target is what makes it different. Glucagon is usually thought of as the hormone that raises blood sugar, but activating its receptor also increases the amount of energy your body burns and appears to pull fat directly out of the liver. So instead of working only by reducing appetite, survodutide combines appetite suppression with a genuine increase in energy expenditure.

What the trial showed

The phase 3 SYNCHRONIZE-1 trial, published in the New England Journal of Medicine in June 2026, followed adults with obesity — or overweight with a weight-related condition, excluding diabetes — for 76 weeks.

• Average weight loss of 16.6%, compared with 3.2% on placebo
• Up to 85% of participants lost at least 5% of their body weight
• Visceral fat fell by up to 34% — the deep abdominal fat that drives metabolic disease
• Liver fat fell by up to 63%
• Lean mass loss was limited, accounting for no more than 11.3% of the total tissue lost at the highest dose

The two numbers that matter most

The headline 16.6% places survodutide below tirzepatide (~20%) and roughly alongside semaglutide (~15%). On weight alone, it is not the most powerful option.

But look at the other two figures. A 34% reduction in visceral fat and a limited loss of lean mass matter more than the number on the scale. I have written before about how muscle loss during rapid weight loss leaves patients thinner but weaker. A medication that removes fat from the abdomen and the liver while largely sparing muscle is doing exactly what we want obesity treatment to do — and that is a more meaningful result than a bigger percentage achieved partly at the expense of muscle.

The liver findings are strong enough that survodutide has been studied specifically for fatty liver disease, which I have covered in a separate article.

Side effects and availability

The side-effect profile is the familiar one for this class: nausea, vomiting, diarrhoea and constipation, mostly during dose escalation and mostly mild to moderate. Slow, gradual dose increases remain the way to manage them.

Survodutide is not yet approved anywhere, including Kuwait. It is completing its regulatory pathway, and until it is approved there is no legitimate supply. Anything sold online claiming to be survodutide is unregulated and unsafe — I would say exactly the same about retatrutide, and for the same reasons.

What to do in the meantime

If you are waiting for survodutide, do not wait idly. The approved options today — tirzepatide, semaglutide, the oral GLP-1 tablets, endoscopic procedures and surgery — are effective, well studied and available now, and starting treatment does not prevent you from switching later when new options arrive.

The right question is not "which drug is strongest" but "which treatment fits my body, my conditions and my life." That is a conversation, not a headline.

This article is educational and does not replace personalized medical advice. To discuss your options, contact Professor Jamal's clinic on WhatsApp +965 60621662.